Upper GI Endoscopy Surveillance in Decompensated Cirrhosis with Small Varices

Rationale for Annual Surveillance

Patients with decompensated cirrhosis have a significantly higher risk of variceal progression and bleeding compared to those with compensated disease, with 72% having gastroesophageal varices, according to the European Association for the Study of the Liver 1, 2
Small varices progress to large varices at a rate of 12% after 1 year and up to 22% at one year in patients with Child B/C cirrhosis, as reported by the Clinical and Molecular Hepatology 3
The progression rate from small to large varices can reach 51% at three years in patients with Child B/C cirrhosis, especially with alcoholic etiology and/or red wale marks, according to the Journal of Hepatology 1

The European Association for the Study of the Liver (EASL) recommends that in the presence of decompensated cirrhosis, EGD should be repeated at yearly intervals 4, 5
The Korean Association for the Study of the Liver (KASL) guidelines recommend that endoscopic surveillance should be performed at 1–2-year intervals in those with decompensated liver cirrhosis 3, 6
The American Association for the Study of Liver Diseases (AASLD) guidelines note that patients with small varices who develop decompensation should have a repeat endoscopy when decompensation occurs 7

Alcoholic etiology of cirrhosis is a risk factor for rapid progression from small to large varices, as reported by the Journal of Hepatology 1
Presence of red wale marks on varices is a risk factor for rapid progression from small to large varices, according to Hepatology 8, 1
Ongoing liver injury (e.g., continued alcohol consumption) is a risk factor for rapid progression from small to large varices, as noted by the American Association for the Study of Liver Diseases (AASLD) 7
Higher Child-Pugh score (B or C) is a risk factor for rapid progression from small to large varices, according to the Clinical and Molecular Hepatology 3

Non-selective beta-blockers (NSBBs) should be used in patients with small varices that have high-risk features (Child B/C or red wale marks), as recommended by Hepatology 8
If NSBBs are used appropriately, the need for surveillance endoscopies may be reduced, according to Hepatology 8

Esophageal capsule endoscopy may eventually replace conventional endoscopy for surveillance, though its sensitivity remains to be established, as reported by Hepatology 4, 5
Non-invasive markers (platelet count, spleen size, portal vein diameter, transient elastography) show promise but currently have unsatisfactory predictive accuracy, according to Hepatology 4, 5

Cost-effectiveness analyses have suggested universal beta-blocker therapy without screening EGD for patients with decompensated cirrhosis, but this approach has not been prospectively validated, as noted by Hepatology 4
Patients already on non-selective beta-blockers for other reasons may not need surveillance endoscopy as frequently, according to Hepatology 4
If a patient is on a selective beta-blocker (metoprolol, atenolol), switching to a non-selective agent (propranolol, nadolol) would be necessary for variceal prophylaxis, as recommended by Hepatology 4